- Home
- CPZ vs ALDX Comparison
CPZ vs ALDX Comparison
Compare CPZ & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPZ
- ALDX
- Stock Information
- Founded
- CPZ 2019
- ALDX 2004
- Country
- CPZ United States
- ALDX United States
- Employees
- CPZ N/A
- ALDX N/A
- Industry
- CPZ Trusts Except Educational Religious and Charitable
- ALDX Biotechnology: Pharmaceutical Preparations
- Sector
- CPZ Finance
- ALDX Health Care
- Exchange
- CPZ Nasdaq
- ALDX Nasdaq
- Market Cap
- CPZ 300.6M
- ALDX 304.9M
- IPO Year
- CPZ N/A
- ALDX 2014
- Fundamental
- Price
- CPZ $15.66
- ALDX $6.58
- Analyst Decision
- CPZ
- ALDX Strong Buy
- Analyst Count
- CPZ 0
- ALDX 2
- Target Price
- CPZ N/A
- ALDX $10.00
- AVG Volume (30 Days)
- CPZ 63.0K
- ALDX 666.8K
- Earning Date
- CPZ 01-01-0001
- ALDX 05-01-2025
- Dividend Yield
- CPZ 11.07%
- ALDX N/A
- EPS Growth
- CPZ N/A
- ALDX N/A
- EPS
- CPZ N/A
- ALDX N/A
- Revenue
- CPZ N/A
- ALDX N/A
- Revenue This Year
- CPZ N/A
- ALDX N/A
- Revenue Next Year
- CPZ N/A
- ALDX N/A
- P/E Ratio
- CPZ N/A
- ALDX N/A
- Revenue Growth
- CPZ N/A
- ALDX N/A
- 52 Week Low
- CPZ $13.17
- ALDX $2.75
- 52 Week High
- CPZ $16.11
- ALDX $7.20
- Technical
- Relative Strength Index (RSI)
- CPZ 58.12
- ALDX 53.63
- Support Level
- CPZ $15.57
- ALDX $6.22
- Resistance Level
- CPZ $15.78
- ALDX $6.87
- Average True Range (ATR)
- CPZ 0.23
- ALDX 0.46
- MACD
- CPZ 0.03
- ALDX -0.03
- Stochastic Oscillator
- CPZ 81.06
- ALDX 60.51
About CPZ Calamos Long/Short Equity & Dynamic Income Trust
Calamos L/S Equity & Dynamic Inc Trust is a trust company which seeks to provide current income and risk-managed capital appreciation. The company invests in securities across sectors such as Industrials, Healthcare, Financials, Consumer Discretionary and others.
About ALDX Aldeyra Therapeutics Inc.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.